PhosphoPlus RRM2 (Thr33) Antibody Duet

Ribonucleotide reductase catalyzes the rate-limiting step in the synthesis of deoxynucleotide triphosphates (dNTPs). Ribonucleoside-diphosphate reductase subunit M2 (RRM2) is frequently overexpressed and associated with poor prognosis in multiple human cancers (1). RRM2/AKT/NF-κB signaling pathway is implicated in tumor invasiveness in gastric cancer (2). RRM2 is highly expressed in melanoma, and correlated with poor prognosis in BRAF-mutant melanoma. Knockdown of RRM2 stabilized the transient response of cells and patient-derived xenograft (PDX) model system to BRAF inhibition (3).Cyclin-dependent kinase (CDK) mediated phosphorylation of RRM2 at Thr33 targets the protein for degradation, allowing cells to maintain balanced dNTP pools (4). 1.Furuta, E. et al. (2010) Biochim Biophys Acta 1805, 141-52. 2.Zhong, Z. et al. (2016) Pharmazie 71, 280-4. 3.Fatkhutdinov, N. et al. (2016) Mol Cancer Res 14, 767-75. 4.D'Angiolella, V. et al. (2012) Cell 149, 1023-34.